• English

上海凡默谷信息技术有限公司

上海凡默谷信息技术有限公司

上海市

021-50263208
客服微信:ipharmogo

周一至周五 9:00~19:00

解决方案
  • 首页
  • 关于我们
    • 公司简介
    • 典型用户
    • 合作伙伴
  • 新闻资讯
    • 培训通知
    • 公司动态
  • 产品中心
    • GastroPlus
    • ADMET Predictor
    • DDDPlus
    • DILIsym
    • MonolixSuite
    • 其他产品
  • 培训中心
    • 视频汇总
    • 技术视频
    • 技术文章
    • 使用FAQ
    • 历年文献汇总
  • 在线申请
  • 联系我们
  • 首页
  • 关于我们
    • 全部
    • 公司简介
    • 典型用户
    • 合作伙伴
  • 新闻资讯
    • 全部
    • 培训通知
    • 公司动态
  • 产品中心
    • 全部
    • GastroPlus
    • ADMET Predictor
    • DDDPlus
    • DILIsym
    • MonolixSuite
    • 其他产品
  • 培训中心
    • 全部
    • 视频汇总
    • 技术视频
    • 技术文章
    • 使用FAQ
    • 历年文献汇总
  • 在线申请
    • 全部
  • 联系我们
    • 全部
GastroPlus在预测特定人群PK的应用文章 (2011—2020年10月)
  1. 您现在所在位置:
  2. 网站首页
  3. GastroPlus系列文章汇总

GastroPlus在预测特定人群PK的应用文章 (2011—2020年10月)

2020-10-15 18:35:05

导  读


凡默谷技术部精取了2011-2020年10月GastroPlus在预测特定人群PK的应用文章35篇。

其中编号1-8的文章是2019年8月-2020年10月新增的文章。

希望对您的业务或专业学习有所帮助。内容如下:

1.  使用生理药代动力学吸收模型建立奥司他韦在成人和儿童人群中的生物等效性溶出安全空间
Using a Physiologically Based Pharmacokinetic Absorption Model to Establish Dissolution Bioequivalence Safe Space for Oseltamivir in Adult and Pediatric Populations
Lei Miao, Youssef M. Mousa, Liang Zhao, Kimberly Raines, Paul Seo, Fang Wu. The AAPS Journal. volume 22, Article number: 107 (2020). IF= 3.737

2.  生理药代动力学PBPK模型在儿科领域:开始走向成熟?

Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
Verscheijden LFM, Koenderink JB, Johnson TN, de Wildt SN, Russel FGM.Pharmacol Ther.  (2020) 107541. IF= 10.557

3.  在肾功能不全的儿童患者中的厄他培南生理药代动力学PBPK模型

A Physiologically Based Pharmacokinetic Model of Ertapenem in Pediatric Patients With Renal Impairment.
Lingling Ye, Meng Ke, Xiang You, Pinfang Huang, Cuihong Lin
Journal of Pharmaceutical Sciences. Volume 109, Issue 9, September 2020, Pages 2909-2918. IF= 2.997

4.  口服扑热息痛小儿亲水性悬浮液后,进行成人到婴儿体内暴露的成功外推在很大程度上取决于研究中的给药条件

Successful Extrapolation of Paracetamol Exposure from Adults to Infants After Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the Study Dosing Conditions.
Marina Statelova, René Holm, Nikoletta Fotaki, Christos Reppas, Maria Vertzoni.AAPS J. 2020 Sep 30;22(6):126. IF= 3.737

5.  使用生理药代动力学PBPK模型模拟奥司他韦及其活性代谢物在正常和肝硬化患者中的药代动力学

Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling.
Yong Chen, Meng Ke, Jianwen Xu, Cuihong Lin. AAPS PharmSciTech. 2020 Mar 3;21(3):98. IF=2.401

6.   采用生理药代动力学PBPK模型预测普拉克索Pramipexole在帕金森氏病肾功能不全患者中的药代动力学

Development of a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment.
Xiang You, Wanhong Wu, Jing Xu, Zheng Jiao, Meng Ke, Pinfang Huang, Cuihong Lin. J Clin Pharmacol. 2020 Aug;60(8):999-1010. IF=4.193

7.  研究肝脏磺基转移酶个体发育,并预测年龄对对乙酰氨基酚硫酸化代谢贡献的百分数

Ontogeny of Hepatic Sulfotransferases and Prediction of Age-Dependent Fractional Contribution of Sulfation in Acetaminophen Metabolism.
Mayur K. Ladumor, Deepak Kumar Bhatt, Andrea Gaedigk, Sheena Sharma, Aarzoo Thakur, Robin E. Pearce, J. Steven Leeder, Michael B. Bolger, Saranjit Singh and Bhagwat Prasad.
Drug Metabolism and Disposition. August 2019, 47 (8) 818-831. IF=3.232

8.   采用生理药代动力学PBPK模型,评估影响美托洛尔缓释药品生物等效性的制剂因素

Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended-Release Products.
Sumit Basu, Haitao Yang, Lanyan Fang, Mario Gonzalez‐Sales, Liang Zhao, Mirjam N. Trame, Lawrence Lesko, Stephan Schmid.
J Clin Pharmacol. Volume59, Issue9. September 2019 Pages 1252-1263.  IF=2.425

9.   采用结合药效学的PBPK模型预测替卡格雷及其活性代谢物在肝硬化人群中的情况

Prediction of ticagrelor and its active metabolite in liver cirrhosis populations using a physiologically based pharmacokinetic model involving pharmacodynamics.
Zhang M, You X, Lin C, Ke M, Jiao Z, Wu H, Huang P. J Pharm Sci. Mar 27, 2019.IF=3.616

10.  咖啡因在孕妇体内处置的PBPK/PD模型

Physiologically Based Pharmacokinetic/ Pharmacodynamic Model for Caffeine Disposition in Pregnancy.
Darakjian LI, Kaddoumi A. Mol Pharm. Jan 28, 2019. IF=4.321

11.   开发用于儿科药品的生理药代动力学PBPK模型:现状和挑战

Pediatric Physiologically Based Pharmacokinetic Model Development: Current Status and Challenges.
Lin W, Yan JE, Heimbach T, He H. Current Pharmacology Reports. December 2018, Volume 4, Issue 6, pp 491–501.


12.   通过PBPK和模型中的虚拟人群考察生理学对曲马多Tramadol儿科PK预测的影响


PBPK and its Virtual Populations: the Impact of Physiology on Pediatric Pharmacokinetic Predictions of Tramadol. 

T’jollyn H, Vermeulen A, Van Bocxlaer J. AAPS J. January 2019, 21:8. IF=3.737


13.   通过整合的PBPK模型,对比达沙替尼Dasatinib不同的儿科用药制剂的生物等效性,并阐明相应的吸收机制


Bioequivalence comparison of pediatric Dasatinib formulations and elucidation of absorption mechanisms through integrated PBPK modeling. 

Vaidhyanathan S, Wang X, Crison JR, Varia S, Gao J, Saxena A, Good D. J Pharm Sci. January 2019 Volume 108, Issue 1, Pages 741–749. IF=3.616


14.  使用酮康唑作为模型药物的计算机工具在临床实践中的应用


Application of in silico Tools in Clinical Practice using Ketoconazole as a Model Drug. 

Silva DA, Duque MD, Davies NM, Löbenberg R, Ferraz HG. J Pharm Pharm Sci.2018;21(1s):242s-253s. IF=0.69


15.  在评估儿科口服药品中生物药剂学的考虑因素-PEARRL综述


Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products – a PEARRL review. 

Guimarães M, Statelova M, Holm R, Reppas C, Symilllides M, Vertzoni M, Fotaki N.J Pharm Pharmacol. 2018 Jul 3. IF=2.571


16.   用于考察普通病人、重症监护病房和肝功能不全患者的全身生理药代动力学PBPK模型,以卡泊芬净Caspofungin为案例


Whole-body physiology-based pharmacokinetics of caspofungin for general patients, intensive care unit patients and hepatic insufficiency patients.

Yang QT, Zhai YJ, Chen L, Zhang T, Yan Y, Meng T, Liu LC, Chen LM, Wang X, Dong YL. Acta Pharmacol Sin. 2018 May 31. IF=1.736


17.   mTORC1 / 2抑制剂sapanisertib(TAK-228)口服研磨制剂的I期研究:在晚期实体瘤患者中的耐受性和食物效应


Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.

Moore KN, Bauer TM, Falchook GS, Chowdhury S, Patel C, Neuwirth R, Enke A, Zohren F, Patel MR. ESMO Open. 2018 Feb 1;3(2): e000291.


18.   在长期服用厄洛替尼erlotinib的期间,监测在胰腺癌患者中的行为,并与生理药代动力学PBPK模型的预测结果进行比较


Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.

Gruber A, Czejka M, Buchner P, Kitzmueller M, Kirchbaumer Baroian N, Dittrich C, Sahmanovic Hrgovcic A. Cancer Chemother Pharmacol. 2018 Apr;81(4):763-771.IF=2.967


19.   考察口服卡马西平在儿童人群中的吸收


Investigating Oral Absorption of Carbamazepine in Pediatric Populations. 

Kohlmann P, Stillhart C, Kuentz M, Parrott N. AAPS J. 2017 Nov;19(6):1864-1877.IF=3.737


20.  用于促进弱碱性药物制剂处方开发的生物相关性溶出模型,并克服因胃酸分泌过少或胃酸缺乏导致的低生物利用度


Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or Achlorhydria. 

Kou D, Dwaraknath S, Fischer Y, Nguyen D, Kim M, Yiu H, Patel P, Ng T, Mao C, Durk M, Chinn L, Winter H, Wigman L, Yehl P. Mol Pharm. 2017 Oct 2;14(10):3577-3587. IF=4.321


21.  开发具有非典型分布行为的药物的PBPK模型及资质:以地昔帕明为例


Development and qualification of physiologically based pharmacokinetic models for drugs with atypical distribution behavior: A desipramine case study.

Samant T S, Lukacova V, Schmidt S. CPT: Pharmacometrics & Systems Pharmacology, 2017. CiteScore=5.2


22.   Danirixin盐型药物在降低患者群体中的PK变异度因素的识别和表征


Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations.

Bloomer J C, Ambery C, Miller B E, et al. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 117: 224-231.  IF=4.604


23.  采用计算机模拟了解肾功能损伤对二甲双胍口服吸收影响的机制


Mechanistic understanding of the effect of renal impairment on metformin oral absorption using computer simulations. 

Almukainzi M, Gabr R, Abdelhamid G, et al. Journal of Pharmaceutical Investigation, 2017, 47(2): 151-161.


24.  采用机制性吸收模型研究哌甲酯口服缓释制剂在成人体内的药动学曲线


Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults. 

Yang X, Duan J, Fisher.J. PloS one, 2016, 11(10): e0164641. IF=2.74


25. 用于预测更昔洛韦及其前药缬更昔洛韦在成人和儿童体内行为的生理药代动力学PBPK模型


A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children.

Lukacova V, Goelzer P, Reddy M, et al. The AAPS journal, 2016, 18(6): 1453-1463.IF=3.737


26.  通过特定疾病的模型模拟美洛昔康和布洛芬在不同疾病状态与健康状况下的PK


Disease specific modeling: simulation of the pharmacokinetics of meloxicam and ibuprofen in disease state vs. healthy conditions. 

Almukainzi M, Jamali F, Aghazadeh-Habashi A, Löbenberg R. (2016) Eur. J. Pharm. Biopharm. Jan. 2. IF=4.604


27. 用于儿科肿瘤药物开发的生理药代动力学PBPK模型


Physiologically-Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development. 

 Rioux N, Waters NJ. (2016) Drug Metab Dispos. Mar 2. IF=3.231


28.  使用生理药代动力学PBPK模型深入了解生理因素对口服药物在儿童人群中吸收的影响


Using Physiologically Based Pharmacokinetic (PBPK) Modelling to Gain Insights into the Effect of Physiological Factors on Oral Absorption in Paediatric Populations. 

Villiger A, Stillhart C, Parrott N, Kuentz M. (2016) AAPS J. Apr 8. IF=3.737


29.  开发用于预测吲哚美辛在孕妇体内处置的PBPK/PD模型


Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy. 

Alqahtani S, Kaddoumi A. (2015). PLoS One. Oct 2;10(10). IF=2.74


30.  氧化物酶体增殖物激活受体PPAR的神经保护作用,用于治疗帕金森病认知障碍中的PPAR激动剂:行为,生物化学和PBPK预测曲线

Neuroprotective Potential of Peroxisome Proliferator Activated Receptor-a Agonist in Cognitive Impairment in Parkinson’s Disease: Behavioral, Biochemical, and PBPK Profile. 

Uppalapati D, Das NR, Gangwal RP, Damre MV, Sangamwar AT, Sharma SS. (2014)PPAR Research; Article ID 753587. IF=2.953


31.  模拟胃肠道旁路手术后患者服用二甲双胍后的吸收


Modelling the Absorption of Metformin with Patients Post Gastric Bypass Surgery. 

Almukainzi M, Lukacova V, Löbenberg R. (2014) J Diabetes Metab. 5:353.IF=3.099


32.   PPAR-β/ d激动剂具有神经保护作用,可减少啮齿动物帕金森病模型的认知障碍


A PPAR-ß/d Agonist is Neuroprotective and Decreases Cognitive Impairment in a Rodent Model of Parkinson's Disease.

Das NR, Gangwal RP, Damre MV, Sangamwar AT, Sharma SS. (2014). Curr Neurovasc Res. Mar 18. IF=1.649


33.  采用简化的PBPK建模方法,预测主要经肾排泄和CYP3A代谢的四种化合物在妊娠期间的PK


A Simplified PBPK Modeling Approach for Prediction of Pharmacokinetics of Four Primarily Renally Excreted and CYP3A Metabolized Compounds During Pregnancy. 

Xia B, Heimbach T, Gollen R, Nanavati C, He H. (2013) AAPS J. Jul 9. IF=3.737


34.  开发奥司他韦基于生理学的模型,并用于模拟在新生儿和婴儿的PK


Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. 

Parrott N, Davies B, Hoffmann G, Koerner A, Lave T, Prinssen E, Theogaraj E, Singer T. (2011). Clin Pharmacokinet. 50(9):613-23. IF=4.604


35.  生理药代动力学PBPK模型:方法论,应用和局限性,重点关注其在儿科药物开发中的作用


Physiologically Based Pharmacokinetic Modeling: Methodology, Applications, and Limitations with a Focus on Its Role in Pediatric Drug Development.

Khalil F, Läer S.(2011) J Biomed Biotechnol. 2011: 907461. IF=2.276


点击查看其他文献


  • GastroPlus在FDA等法规部门的应用文章(2016-2020)

  • GastroPlus在PBPK、ACAT、PBBM模型应用的综述文章(2011-2020)

  • 采用GastroPlus预测PK曲线或PK参数的应用文章(2011-2020)

  • GastroPlus在口服吸收、制剂开发等的应用文章(2011—2020)

  • GastroPlus在IVIVC, IVIVR, BE考察的应用文章(2012—2020)

  • GastroPlus在PK-PD结合模型的应用文章(2012—2020)

  • GastroPlus在预测特定人群PK的应用文章(2011—2020)

  • GastroPlus在预测药物相互作用DDI的应用文章(2011 —2020)

  • GastroPlus在考察食物效应的应用文章(2013—2020)

  • GastroPlus在考特殊给药途径的应用文章(2012—2020)

  • GastroPlus在毒理领域的应用文章(2012年—2020年10月)

  • 评估GastroPlus预测准确性的应用(2011年—2020年 10月)

  • 中国用户采用GastroPlus发表的应用文章(2013年—2020年10月)




  • 上一页: GastroPlus在PK-PD结合模型的应用文章 (2012—2020年10月)
  • 下一页: GastroPlus 在预测药物相互作用DDI 的应用文章 (2011 —2020 )
logo
  • 上海市
  • 021-50263208
  • 客服微信:ipharmogo

快捷导航

  • 关于我们
  • 新闻资讯
  • 产品中心
  • 培训中心
  • 在线申请
  • 联系我们

关注公众号
了解更多资讯

本站基于 米拓企业建站系统搭建 7.9 ©2008-2024 www.mituo.cn    沪ICP备12013663号-1

电话咨询
产品中心
新闻资讯
QQ客服